A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer
Tak Yun, Heung Tae Kim, Ji-Youn Han, Sung Jin Yoon, Hyae Young Kim, Byung-Ho Nam, Jin Soo Lee
Cancer Res Treat. 2016;48(2):465-472. Published online 2015 May 26 DOI: https://doi.org/10.4143/crt.2015.061
Citations to this article as recorded by 
Impact of nab-paclitaxel plus PD-1/PD-L1 inhibitor on chemorefractory relapsed small-cell lung cancer
Fengchun Mu, Bingjie Fan, Haoqian Li, Wenru Qin, Chunni Wang, Bing Zou, Linlin Wang
Future Oncology.2023;[Epub] CrossRef
Iron oxide nanoparticles induce ferroptosis via the autophagic pathway by synergistic bundling with paclitaxel
Qi Nie, Wenqing Chen, Tianmei Zhang, Shangrong Ye, Zhongyu Ren, Peng Zhang, Jian Wen
Molecular Medicine Reports.2023;[Epub] CrossRef
Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy
Zhonglin Hao, Janeesh Sekkath Veedu
Clinical Lung Cancer.2022; 23(1): 14. CrossRef
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis
Jan A. Stratmann, Radha Timalsina, Akin Atmaca, Vivian Rosery, Nikolaj Frost, Jürgen Alt, Cornelius F. Waller, Niels Reinmuth, Gernot Rohde, Felix C. Saalfeld, Aaron Becker von Rose, Fabian Acker, Lukas Aspacher, Miriam Möller, Martin Sebastian
Therapeutic Advances in Medical Oncology.2022; 14: 175883592210971. CrossRef
Functionalized FcRn-targeted nanosystems for oral drug delivery: A new approach to colorectal cancer treatment
Fatima Hameedat, Nuria A. Pizarroso, Natália Teixeira, Soraia Pinto, Bruno Sarmento
European Journal of Pharmaceutical Sciences.2022; 176: 106259. CrossRef
Comparison of two regimens of weekly paclitaxel plus gemcitabine in patients with metastatic breast cancer: propensity score–matched analysis of real-world data
Chengcheng Gong, Yizhao Xie, Yannan Zhao, Yi Li, Jian Zhang, Leiping Wang, Jun Cao, Zhonghua Tao, Xichun Hu, Biyun Wang
Therapeutic Advances in Drug Safety.2022; 13: 204209862211464. CrossRef
Impact of Nab-Paclitaxel Plus PD-1/PD-L1 Inhibitor Versus Traditional Chemotherapy for Retreatment Small Cell Lung Cancer Patients
Fengchun Mu, Bingjie Fan, Wenru Qin, Shijiang Wang, Bing Zou, Linlin Wang
SSRN Electronic Journal .2022;[Epub] CrossRef
FcRn expression in cancer: Mechanistic basis and therapeutic opportunities
Imke Rudnik-Jansen, Kenneth A. Howard
Journal of Controlled Release.2021; 337: 248. CrossRef
Nanoparticle Albumin Bound Paclitaxel in the Third-Line Treatment of Recurrent Small Cell Lung Cancer in Real-World Practice: A Single Center Experience
Yuchao Wang, Li Li, Chunhua Xu
Technology in Cancer Research & Treatment.2021; 20: 153303382110507. CrossRef
Combination therapy with carboplatin and paclitaxel for small cell lung cancer
Atsuto Mouri, Ou Yamaguchi, Sachiko Miyauchi, Ayako Shiono, Harue Utsugi, Fuyumi Nishihara, Yoshitake Murayama, Hiroshi Kagamu, Kunihiko Kobayashi
Respiratory Investigation.2019; 57(1): 34. CrossRef
Response to and toxicity of gemcitabine for recurrent ovarian cancer according to number of previous chemotherapy regimens
Yuji Takei, Yoshifumi Takahashi, Shizuo Machida, Akiyo Taneichi, Suzuyo Takahashi, Tomomi Nagashima, Hiroyuki Morisawa, Yasushi Saga, Shigeki Matsubara, Hiroyuki Fujiwara
Journal of Obstetrics and Gynaecology Research.2017; 43(2): 358. CrossRef
Second-line treatments of small-cell lung cancers
Nathalie Baize, Isabelle Monnet, Laurent Greillier, Gilles Quere, Mallorie Kerjouan, Henri Janicot, Alain Vergnenegre, Jean Bernard Auliac, Christos Chouaid
Expert Review of Anticancer Therapy.2017; 17(11): 1033. CrossRef